Search clinical trials for: Bintrafusp alfa

Total 3054 results

Instituto Bernabeu

Completed

Follicular Phase Stimulation vs. Luteal Phase Stimulation in Patients Diagnosed With Suboptimal Response (SUBLUTEAL)

Improving Ovarian Stimulation; Suboptimal Responders

Spain
AO GENERIUM

Completed

Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

Fibrosis | Cystic Fibrosis

Russian Federation
Hoffmann-La Roche

Completed

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Hepatitis C, Chronic

Israel
Amgen

Completed

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Anemia | Non-Myeloid Malignancies
Eli Lilly and Company

Completed

Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

Sepsis | Hypotension

France, United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

Brain and Central Nervous System Tumors

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) (AHEAD)

Hemophilia A

Czechia, Switzerland, Denmark, Canada, Australia, Austria, France, United Kingdom, Italy, Sweden, Belgium, Brazil, China, Colombia, Greece, Hungary, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Ultragenyx Pharmaceutical Inc

Completed

A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)

Mucopolysaccharidosis | Sly Syndrome | Mucopolysaccharidosis VII | MPS VII

United States, Brazil, Mexico, Portugal
Shahid Beheshti University of Medical Sciences
Pooyesh Darou

Completed

Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery

Myocardial Ischemic Reperfusion Injury

Iran, Islamic Republic of
Hoffmann-La Roche

Completed

Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253

Hepatitis B, Chronic

Italy
Merck Sharp & Dohme LLC

Completed

PegIntron Injection Surveillance Plan (Study P04123)

Hepatitis C, Chronic
Amgen

Terminated

Darbepoetin Alfa and Anemia of Cancer

Neoplasms | Carcinoma | Cancer | Anemia | Non-Myeloid Malignancies | Anemia of Cancer
Amgen

Completed

NESP Pediatric Study

End Stage Renal Disease | Pre-dialysis
M.D. Anderson Cancer Center

Withdrawn

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Metastatic HER2 Negative Breast Adenocarcinoma

United States
Sandoz

Completed

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD) (SENSE)

Chronic Kidney Disease

Russian Federation, Germany, Italy, Poland, Romania, Turkey, Ukraine
Hoffmann-La Roche

Completed

A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy

Hepatitis C, Chronic

Germany
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

Non Small Cell Lung Cancer

China
BioMarin Pharmaceutical
ICON plc

Completed

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) (MARS)

Mucopolysaccharidosis IV Type A | Morquio A Syndrome | MPS IVA

United States, United Kingdom, Australia, Taiwan, Belgium, Malaysia, Austria, Canada, Portugal, France, Ireland, Czechia, Denmark, Italy, Netherlands, Poland, Puerto Rico
Genzyme, a Sanofi Company

Completed

Growth and Development Study of Alglucosidase Alfa

Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Pompe Disease

United States
Novo Nordisk A/S

Completed

Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern

Severe Postpartum Haemorrhage

Switzerland
Sandoz

Completed

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa (ACCESS)

Anemia | Chronic Kidney Disease (CKD)

United States
Instituto Valenciano de Infertilidad, IVI VALENCIA

Not yet recruiting

Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA) (TROPIX)

Infertility, Female | Reproductive Sterility

Spain
National Taiwan University Hospital

Recruiting

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

Pre-fibrotic Myelofibrosis

Taiwan
PharmaEssentia

Recruiting

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Essential Thrombocythemia

United States, Canada
Shire

Completed

Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease

Fabry Disease

United States, Slovenia, Australia, Finland, Poland, Czechia, United Kingdom
CSL Behring

Completed

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Congenital Coagulation Factor VII Deficiency

Netherlands, Norway
Guangzhou 8th People's Hospital

Recruiting

Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

Hepatitis B | AIDS

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Hepatitis B, Chronic

China
Ultragenyx Pharmaceutical Inc

Completed

Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

Mucopolysaccharidosis | Sly Syndrome | Mucopolysaccharidosis VII | MPS VII

Spain, United States, Portugal
Hoffmann-La Roche

Completed

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China, Hong Kong, Taiwan, Singapore, Korea, Republic of, New Zealand, Thailand, Brazil, Russian Federation, Australia
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Chronic Hepatitis B

China
National Institute of Diabetes and Digestive and...

Not yet recruiting

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Chronic Hepatitis B

United States
NorthShore University HealthSystem
Chiesi USA, Inc.

Recruiting

Prophylactic Minimally Invasive Surfactant Evaluation (PreProMISe)

Premature Birth | Respiratory Distress Syndrome, Newborn

United States
Virgilio Paolo Carnielli

Not yet recruiting

Medium vs Low Oxygen Threshold for the Surfactant Administration

Respiratory Distress Syndrome
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Childhood Craniopharyngioma

United States
Seng Gee Lim
Roche Pharma AG

Unknown

Peg-interferon for Inactive Chronic Hepatitis B Carriers (INACTIVE)

Chronic Hepatitis, B Virus | Carrier of Viral Hepatitis Type B

Singapore
Amgen

Terminated

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

Anemia

United States
Amgen

Completed

EPO Deep Tank in Dialysis Subjects

Chronic Kidney Disease
Amgen

Completed

A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa

Small Cell Lung Cancer
George Washington University
Eli Lilly and Company

Completed

Safety and Dose Finding Study of Xigris in Hemodialysis Patients (Xigris1003)

End Stage Renal Disease

United States
The Catholic University of Korea
Ulsan University Hospital; Yonsei University; Kyungpook National University Hospital and other collaborators

Completed

100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)

Sustained Virologic Response | IL28B Polymorphism

Korea, Republic of
Fang Wang

Recruiting

A Study on Antiviral Treatment of Chronic Hepatitis B in Children

Chronic HBV Infection

China
Penang Hospital, Malaysia

Unknown

Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'

End Stage Renal Failure | Anaemia
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Merck Sharp & Dohme LLC

Completed

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

Chronic Hepatitis C | Liver Fibrosis
Hoffmann-La Roche

Completed

An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B

Hepatitis B, Chronic

Morocco

Search clinical trials for: Bintrafusp alfa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations